CUSIP: 20600T108
Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
4,223,013
-
Share change
-
-1,008,004
-
Total reported value
-
$1,328,163
-
Put/Call ratio
-
62%
-
Price per share
-
$0.31
-
Number of holders
-
23
-
Value change
-
-$295,384
-
Number of buys
-
4
-
Number of sells
-
16
Quarterly Holders Quick Answers
What is CUSIP 20600T108?
CUSIP 20600T108 identifies CNAT - CONATUS PHARMACEUTICALS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2019
-
Previous quarter:
Q2 2019
Recent filing periods for CUSIP 20600T108:
Institutional Holders of CONATUS PHARMACEUTICALS INC - COM (CNAT) as of Q3 2019
As of 30 Sep 2019,
CONATUS PHARMACEUTICALS INC - COM (CNAT) was held by
23 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,223,013 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock Inc., ACADIAN ASSET MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, Bank of New York Mellon Corp, UNITED CAPITAL FINANCIAL ADVISERS, LLC, BRIDGEWAY CAPITAL MANAGEMENT INC, NORTHERN TRUST CORP, Kalos Management, Inc., and WOLVERINE TRADING, LLC.
This page lists
23
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.